and management plans after expert review in North American studies\(^3\)\(^5\) than in UK series\(^1\) likely reflects greater variation in practice standards in the USA. Review work should ideally occur within the context of a multidisciplinary team (MDT) meeting. Such work is time-consuming and requires the attendance of key radiologists, pathologists, surgeons, physicians and paramedical staff, as well as the support of administrators and clerical staff. Notes, films and slides must all be available and in this forum clinical and pathological information is often brought to light which resolves problems, downgrades the clinical impact of radiological uncertainty or else discussion helps to form management or investigation plans to respond to this. There is little reported research on the value of such meetings but such as it is the data are clear. Clinicians place high value on time spent within such meetings and they are time-effective for radiologists\(^6\)\(^7\).

References

[1] Loughrey GJ, Carrington BM, Anderson H, Dobson MJ, Lo Ying Ping F. The value of specialist oncological radiology review of cross-sectional imaging. Clin Radiol 1999; 54: 149–54.

[2] Royal College of Radiologists. The Use of Computed Tomography in the Initial Investigation of Common Malignancies. London: Council of the Royal College of Radiologists, 1994.

[3] Hricak H, Kalbhen CL, Schiedler JE, Schwartz LH, Yu KK, Adams D. Value of expert interpretation in abdominal oncologic imaging: a multicentre study. Radiological Society of North America 1997 Scientific Programme, 205 (P), Abstract no. 361: 225.

[4] Kalbhen CL, Yetter EM, Olson MC, Posniak HV, Aranha GV. Assessing the resectability of pancreatic carcinoma: the value of reinterpretation abdominal CT performed at other institutions. Am J Roentgenol 1998; 171: 1571–6.

[5] Gollub MJ, Panicek DM, Bach AM, Penalver A, Castellino RA. Clinical importance of reinterpretation of body CT scans obtained elsewhere in patients referred for care at a tertiary cancer center. Radiology 1999; 210: 109–12.

[6] Leung DPY, Dixon AK. Clinico-radiological meetings: are they worthwhile? Clin Radiol 1992; 46: 279–80.

[7] Dalla Palma L, Stacul F, Meduri S, Te Geitung J. Relationships between radiologists and clinicians: results from three surveys. Clin Radiol 2000; 55: 692–5.

The digital object identifier for this article is: 10.1102/1470-7330.2001.018

Ovarian cancer — difficulties in monitoring response

D Michael King

Consultant Radiologist, The Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK

The imaging of malignant disease involves tumour diagnosis, staging, measurement of response and identification of complications. Increasingly, oncologic radiologists are expected to provide objective assessment of change in masses, on serial studies, in order to validate response or resistance to new chemotherapeutic agents. In some cancer centres follow-up examinations make up over 75% of computed tomography (CT) activity.

Objective assessment on CT depends on a somewhat simplistic assumption that those masses that increase in size define disease progression, whereas reduction in tumour size indicates a favourable therapeutic impact. The 1979 WHO Handbook and the 1981 paper by Miller \textit{et al.}\(^1\) identified criteria for bi-dimensional measurements of tumour masses and established the classification of Complete Response (CR), Partial Response (PR), Stable Disease (SD) and Progressive Disease (PD). It has become apparent, however, during the application of these criteria that assessments based on bi-dimensional measurements of one or two marker lesions could result in misleading conclusions, particularly in respect of progressive disease where increasing size of a single lesion might be at variance with favourable change elsewhere. This could lead to an incorrect conclusion that therapy was ineffective. It has also become clear that methods for evaluating change in the size of measurable lesions have not always been universally applied and different observers and even centres could employ different regimes. Husband, Gwyther and Rankin highlighted these features in 1999\(^2\) when they described the problems of bi-dimensional measurements of 3-dimensional masses, as well as the difficulties posed by tumour necrosis and calcification.

In June 1999 a revised version of WHO criteria under the heading ‘Response Evaluation Criteria in Solid Tumours (RECIST criteria)’\(^3\) was published, based on the assessment of up to 10 target lesions, the sum of whose longest diameters define the baseline measurement. The stimulus for this finite objective measurement emanates from the licensing authorities, whose requirements define phase II drug assessment protocols for the pharmaceutical industry. RECIST criteria require the identification up to 10 solid, well-marginated nodules and their repeated identification and assessment of
change on serial CT or MRI examinations. The uni-
dimensional measurement of 10 target lesions on
sequential examinations is laborious and fraught with
potential inaccuracy. The application of these criteria
within a busy cancer imaging unit is at best tedious and
expensive and for some tumours impractical. Outside
well-resourced research units, generously staffed with
expert observers, these criteria appear to have achieved
little practical relevance.

Neither the original WHO criteria nor RECIST take
into account changes in physical characteristics of
the tumour such as cystic degeneration or calcification.
Serial measurements of the diameter of an
involved para-aortic lymph node in metastatic non-
seminomatous testicular tumour may well increase
during effective response to chemotherapy. This is com-
monly due to a degree of cystic degeneration within the
mass. This phenomenon is well documented\cite{4} and in this
situation application of RECIST criteria alone may lead
to incorrect conclusions and for individual cases may be
dangerous. Other metastases, e.g. in the liver, may also
undergo necrosis and sarcomas may also increase in
size when necrosis occurs during effective therapy. The
occasional development of tumour calcification may
have varying implication for the assessment of response
but is not considered in these protocols.

Recent discussion\cite{5} has highlighted potential weak-
nesses in RECIST criteria, particularly in relation to the
inability to determine any functional change resulting
from effective drug activity. Tumour neo-angiogenesis
and cellular metabolic changes require assessment by
new dynamic forms of functional imaging such as
\textsuperscript{18}FDG-PET or \textsuperscript{31}P-magnetic resonance spectroscopy
(MRS). In the vast majority of cancer cases, however,
assessment of response depends on morphological
measurement of appropriate target lesions on serial CT
studies.

Problems of reproducibility are encountered when, on
the basis of Phase II trials subsequent phase III studies
involve several centres and multiple observers.
Gwyther\cite{6,7} has reported the impact of independent
radiological review of image data sets in studies of
Gemcitabine and Topotecan and in both reports showed
that response rates were significantly reduced when
independently reviewed by an expert panel.

The mechanics of these reviews still rely on applica-
tion of WHO criteria of bi-dimensional measurement,
but this task becomes most difficult when the assessment
involves metastatic ovarian cancer. It might be argued
that in this particular disease the application of RECIST
criteria is so fraught with potential inaccuracy that
meaningful objective measurements and conclusions are
scientifically impossible, whether performed by single
observers or review panel. In response to the promulga-
tion of these new guidelines the Gynecologic Cancer
Intergroup have published a recommendation that for
the definition of objective disease progression,
after first-line therapy, the doubling of CA 125 from
the upper limit of normal (or doubling from the
post-treatment nadir) predicts disease progression\cite{9}.

Ovarian cancer is a disease which spreads trans-
coelomically, and is characterized by the development of
abdominal ascites and by widespread peritoneal plaques.
Pleural and pericardial effusions together with cystic
lesions are considered by RECIST to be non-measurable
and these patients are excluded from study populations
unless measurable lesions are present. By excluding these
patients and including unreliable data based on
measurements of ill-defined peritoneal and serosal
plaques, the scientific basis for the assessment of therapeu-
tic response must be flawed at the very outset. At the
very least the exclusion of a significant percentage of
patients because of non-measurable disease skews the
study population. Technical improvements in CT with
the development of spiral technology, combined with
changes in technique and the more widespread use of
intravenous contrast enhancement, mean that a small
volume plaque as thin as 1–2 mm can be demonstrated
and analysed sequentially by an experienced observer
but reproducible, accurate measurement is seldom feas-
able. Whilst discrete tumour nodules may be available in
many cases for serial objective measurement (Fig. 1) the
identification of disease reactivation or progression can
be achieved by recognition of more subtle features such
as increasing thickening of wafer-thin enhancing plaques
of disease applied to the serosa of the bowel (Fig. 2).

It is argued, therefore, that for studies involving phase
II trials in ovarian cancer a more accurate and mean-
ingful method of evaluating therapeutic impact could be
afforded by a subjective review of the whole imaging
data set performed by an external panel made up of
experienced radiologists.

During the observation and attempted measurement
of response on serial CT in many cases of ovarian
cancer, and becoming increasingly frustrated in so
doing, the observation of tumour calcification in associ-
ation with metastatic ovarian cancer became increas-
ingly obvious. This well-recognized entity has not,
hitherto, been subjected to any detailed analysis and in
particular its relationship to treatment is unclear. A
retrospective study has, therefore, been undertaken
examining the temporal relationships of clinical and

![Figure 1](image-url)
radiological features, together with tumour markers in 122 patients who presented with or developed calcification within metastatic ovarian cancer. Changes in soft tissue lesion size and the development of calcification have been correlated with histopathology and outcome. The study group was compared with a control group of 1577 patients who had a CT scan performed at least once during follow-up. A positive relationship between calcification and tumour sub-type was identified with serous tumours, which represented 60% of the calcified group, against 30% in the control. Patients with calcification were generally higher stage than the control group but lower grade. They also had a poorer survival rate.

There did not seem to be any relationship between the development of calcification and chemotherapy and thus it is unusable as a marker of response. Reliable assessment of metastatic ovarian cancer still remains extremely difficult and it is contended that for this disease trial data should be subjected to external panel review.

References
[1] Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–14.
[2] Husband JE, Gwyther SJ, Rankin S. Monitoring tumor response. Abdom Imag 1999; 24: 618–21.
[3] Therasse P, Arbuck SG, Eisenhaur EA et al. New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 2000; 92: 205–16.
[4] Husband JE, Hawkes DJ, Peckham MJ. CT estimations of mean attenuation values and volume in testicular tumours: a comparison with surgical and histologic findings. Radiology 1982; 144: 553–8.
[5] Padhani AR, Husband JE. Are current tumour response criteria relevant for the 21st century? Br J Radiol 2000, 73: 1031–3.
[6] Gwyther SJ, Aapro MS, Hatty SR, Postmus PE, Smith IE. Results of an independent oncology review board of pivotal clinical trials of gemcitabine in non-small cell lung cancer. Anticancer Drugs 1999; 10: 693–8.
[7] Gwyther SJ, Bolis G, Gore M et al. Experience with independent radiological review during a topotecan trial in ovarian cancer. Ann Oncol 1997; 8: 463–8.
[8] Vergote I, Rustin GJS, Eisenhauer G B et al. Correspondence. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 2000; 92: 1534–5.

The digital object identifier for this article is: 10.1102/1470-7330.2001.019

Radiopharmaceuticals in monitoring cancer
Keith E Britton and Maria Granowska

Professor and Reader in Nuclear Medicine, St Bartholomew’s Hospital, Queen Mary School of Medicine and Dentistry, University of London and The Imperial Cancer Research Fund Nuclear Medicine Group, London, UK

Introduction
Normal cells have three basic outcomes: differentiation, division and death. Cancer cells usually have reduced differentiation, increased division and mechanisms to avoid programmed cell death, apoptosis. These properties can be used to monitor cancer by nuclear medicine imaging.

Differentiation
Thyroid cancer cells show a reduced ability to take up radio-iodine compared with normal cells. Thus, all normal thyroid tissue has to be ablated surgically and with radio-iodine in order that the papillary or follicular thyroid cancers show uptake on radioiodine images and for thyroglobulin, Tg, to be a useful serum marker. Monitoring of thyroid cancer used to be done with a tracer amount of radioiodine $^{131}$I. It was found that administration of amounts greater than 185 MBq, 5 mCi may cause stunning, reducing the effectiveness of the large dose of $^{131}$I given for therapy, (5–6 GBq, 150 mCi). However, 185 MBq (or less) $^{131}$I gives a poor count rate signal, so that weakly iodine-avid malignant disease may not be detected. If the Tg is raised, some authorities are giving $^{131}$I therapy in the absence of proof of iodine uptake. Some 50% of such patients show no uptake.

Figure 2

36 Multidisciplinary Symposium — monitoring response to treatment

---

Radiopharmaceuticals in monitoring cancer

Keith E Britton and Maria Granowska

Professor and Reader in Nuclear Medicine, St Bartholomew’s Hospital, Queen Mary School of Medicine and Dentistry, University of London and The Imperial Cancer Research Fund Nuclear Medicine Group, London, UK

Introduction
Normal cells have three basic outcomes: differentiation, division and death. Cancer cells usually have reduced differentiation, increased division and mechanisms to avoid programmed cell death, apoptosis. These properties can be used to monitor cancer by nuclear medicine imaging.

Differentiation
Thyroid cancer cells show a reduced ability to take up radio-iodine compared with normal cells. Thus, all normal thyroid tissue has to be ablated surgically and with radio-iodine in order that the papillary or follicular thyroid cancers show uptake on radioiodine images and for thyroglobulin, Tg, to be a useful serum marker. Monitoring of thyroid cancer used to be done with a tracer amount of radioiodine $^{131}$I. It was found that administration of amounts greater than 185 MBq, 5 mCi may cause stunning, reducing the of effectiveness of the large dose of $^{131}$I given for therapy, (5–6 GBq, 150 mCi). However, 185 MBq (or less) $^{131}$I gives a poor count rate signal, so that weakly iodine-avid malignant disease may not be detected. If the Tg is raised, some authorities are giving $^{131}$I therapy in the absence of proof of iodine uptake. Some 50% of such patients show no uptake.

Figure 2

36 Multidisciplinary Symposium — monitoring response to treatment

---

Radiopharmaceuticals in monitoring cancer

Keith E Britton and Maria Granowska

Professor and Reader in Nuclear Medicine, St Bartholomew’s Hospital, Queen Mary School of Medicine and Dentistry, University of London and The Imperial Cancer Research Fund Nuclear Medicine Group, London, UK

Introduction
Normal cells have three basic outcomes: differentiation, division and death. Cancer cells usually have reduced differentiation, increased division and mechanisms to avoid programmed cell death, apoptosis. These properties can be used to monitor cancer by nuclear medicine imaging.

Differentiation
Thyroid cancer cells show a reduced ability to take up radio-iodine compared with normal cells. Thus, all normal thyroid tissue has to be ablated surgically and with radio-iodine in order that the papillary or follicular thyroid cancers show uptake on radioiodine images and for thyroglobulin, Tg, to be a useful serum marker. Monitoring of thyroid cancer used to be done with a tracer amount of radioiodine $^{131}$I. It was found that administration of amounts greater than 185 MBq, 5 mCi may cause stunning, reducing the of effectiveness of the large dose of $^{131}$I given for therapy, (5–6 GBq, 150 mCi). However, 185 MBq (or less) $^{131}$I gives a poor count rate signal, so that weakly iodine-avid malignant disease may not be detected. If the Tg is raised, some authorities are giving $^{131}$I therapy in the absence of proof of iodine uptake. Some 50% of such patients show no uptake.

Figure 2

36 Multidisciplinary Symposium — monitoring response to treatment

---

Radiopharmaceuticals in monitoring cancer

Keith E Britton and Maria Granowska

Professor and Reader in Nuclear Medicine, St Bartholomew’s Hospital, Queen Mary School of Medicine and Dentistry, University of London and The Imperial Cancer Research Fund Nuclear Medicine Group, London, UK

Introduction
Normal cells have three basic outcomes: differentiation, division and death. Cancer cells usually have reduced differentiation, increased division and mechanisms to avoid programmed cell death, apoptosis. These properties can be used to monitor cancer by nuclear medicine imaging.

Differentiation
Thyroid cancer cells show a reduced ability to take up radio-iodine compared with normal cells. Thus, all normal thyroid tissue has to be ablated surgically and with radio-iodine in order that the papillary or follicular thyroid cancers show uptake on radioiodine images and for thyroglobulin, Tg, to be a useful serum marker. Monitoring of thyroid cancer used to be done with a tracer amount of radioiodine $^{131}$I. It was found that administration of amounts greater than 185 MBq, 5 mCi may cause stunning, reducing the of effectiveness of the large dose of $^{131}$I given for therapy, (5–6 GBq, 150 mCi). However, 185 MBq (or less) $^{131}$I gives a poor count rate signal, so that weakly iodine-avid malignant disease may not be detected. If the Tg is raised, some authorities are giving $^{131}$I therapy in the absence of proof of iodine uptake. Some 50% of such patients show no uptake.

Figure 2

36 Multidisciplinary Symposium — monitoring response to treatment

---

Radiopharmaceuticals in monitoring cancer

Keith E Britton and Maria Granowska

Professor and Reader in Nuclear Medicine, St Bartholomew’s Hospital, Queen Mary School of Medicine and Dentistry, University of London and The Imperial Cancer Research Fund Nuclear Medicine Group, London, UK

Introduction
Normal cells have three basic outcomes: differentiation, division and death. Cancer cells usually have reduced differentiation, increased division and mechanisms to avoid programmed cell death, apoptosis. These properties can be used to monitor cancer by nuclear medicine imaging.

Differentiation
Thyroid cancer cells show a reduced ability to take up radio-iodine compared with normal cells. Thus, all normal thyroid tissue has to be ablated surgically and with radio-iodine in order that the papillary or follicular thyroid cancers show uptake on radioiodine images and for thyroglobulin, Tg, to be a useful serum marker. Monitoring of thyroid cancer used to be done with a tracer amount of radioiodine $^{131}$I. It was found that administration of amounts greater than 185 MBq, 5 mCi may cause stunning, reducing the of effectiveness of the large dose of $^{131}$I given for therapy, (5–6 GBq, 150 mCi). However, 185 MBq (or less) $^{131}$I gives a poor count rate signal, so that weakly iodine-avid malignant disease may not be detected. If the Tg is raised, some authorities are giving $^{131}$I therapy in the absence of proof of iodine uptake. Some 50% of such patients show no uptake.

Figure 2

36 Multidisciplinary Symposium — monitoring response to treatment

---

Radiopharmaceuticals in monitoring cancer

Keith E Britton and Maria Granowska

Professor and Reader in Nuclear Medicine, St Bartholomew’s Hospital, Queen Mary School of Medicine and Dentistry, University of London and The Imperial Cancer Research Fund Nuclear Medicine Group, London, UK

Introduction
Normal cells have three basic outcomes: differentiation, division and death. Cancer cells usually have reduced differentiation, increased division and mechanisms to avoid programmed cell death, apoptosis. These properties can be used to monitor cancer by nuclear medicine imaging.

Differentiation
Thyroid cancer cells show a reduced ability to take up radio-iodine compared with normal cells. Thus, all normal thyroid tissue has to be ablated surgically and with radio-iodine in order that the papillary or follicular thyroid cancers show uptake on radioiodine images and for thyroglobulin, Tg, to be a useful serum marker. Monitoring of thyroid cancer used to be done with a tracer amount of radioiodine $^{131}$I. It was found that administration of amounts greater than 185 MBq, 5 mCi may cause stunning, reducing the of effectiveness of the large dose of $^{131}$I given for therapy, (5–6 GBq, 150 mCi). However, 185 MBq (or less) $^{131}$I gives a poor count rate signal, so that weakly iodine-avid malignant disease may not be detected. If the Tg is raised, some authorities are giving $^{131}$I therapy in the absence of proof of iodine uptake. Some 50% of such patients show no uptake.